Related references
Note: Only part of the references are listed.PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Daniela Miricescu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy
Madeline M. Cook et al.
ONCOLOGIST (2021)
Efficacy of everolimus in patientswith HRD/HER2-high risk early stage breast cancer
T. Bachelot et al.
ANNALS OF ONCOLOGY (2021)
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES
Young-Hyuck Im et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
Marc Thill et al.
BREAST CARE (2021)
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2-advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
Guenther G. Steger et al.
BREAST (2020)
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
E. Ciruelos et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
Hans Tesch et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study
Vicky E. Jones et al.
ONCOLOGIST (2019)
Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
Ying Zhang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Everolimus plus exemestane for HR plus advanced breast cancer in routine clinical practice-Final results from the non-interventional trial, BRAWO
D. Lueftner et al.
CANCER RESEARCH (2019)
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial
Hope S. Rugo et al.
LANCET ONCOLOGY (2017)
Analysis of everolimus starting dose as prognostic marker in HR plus mBC patients treated with everolimus (EVE) plus exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.
Peter A. Fasching et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2016)
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2014)
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Denise A. Yardley et al.
ADVANCES IN THERAPY (2013)
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
Howard A. Burris et al.
CANCER (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
